Abstract
Atrial fibrillation (AF) patients with mid-range left ventricular ejection fraction (mrEF) of 40–49% have neither preserved (pEF > 50%) nor reduced (rEF < 40%) EF and are increasingly being recognized as a distinct group with specific clinical risks. We aimed to retrospectively investigate clinical characteristics and associated thrombotic, bleeding and mortality risks of mrEF in comparison to pEF and rEF in a cohort of 1000 non-valvular AF patients presenting in our institution during the period 2013–2018. Patients with mrEF presented with older age (P < 0.001) and a higher frequency of arterial hypertension (P = 0.001) in comparison to both pEF and rEF patients. In comparison to pEF, mrEF patients were more likely to have diabetes mellitus (P = 0.004), lower HDL-cholesterol (P < 0.001) and lower estimated glomerular filtration rate (P < 0.001), significantly higher CHA2DS2-VASC score (P < 0.001), significantly higher HAS-BLED score (P = 0.002) and had a higher likelihood of receiving anticoagulant therapy, mostly warfarin (P = 0.001). In addition, mrEF patients had a significantly higher risk of thrombotic events (HR = 2.22; P = 0.015), death (HR = 1.71; P = 0.005) and composite endpoint of thrombosis, bleeding or death (HR = 1.65; P = 0.003) in comparison to pEF patients, but did not significantly differ in comparison to rEF patients. There was no significant difference regarding major bleeding risk. Associations with clinical outcomes remained statistically significant in multivariate models independently of CHA2DS2-VASC. Our findings support defining AF patients with mrEF as a subgroup with distinct clinical characteristics and increased risk for thrombotic events and death, irrespective of predetermined CHA2DS2-VASC risk. These patients seem to require special clinical considerations and more intensive control of cardiovascular risk factors.
Similar content being viewed by others
References
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in partnership with the European society of cardiology and in collaboration with the European heart Rhythm association and the heart rhythm society. J Am Coll Cardiol 57(11):e101–198
Tomlin AM, Lloyd HS, Tilyard MW (2017) Atrial fibrillation in New Zealand primary care: prevalence, risk factors for stroke and the management of thromboembolic risk. Eur J Prev Cardiol 24(3):311–319
Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN (1993) Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl):94–101
Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C, LeJemtel TH (1993) Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 126(1):141–146
Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Seferovic PM, Maggioni AP, De Mora MM, Polonski L, Silva-Cardoso J, Amir O, Investigators E-HHL-TR (2018) Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European society of cardiology heart failure long-term registry. Eur Heart J 39(48):4277–4284
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M, Document R (2016 ) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093–1100
Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694
Lucijanic M (2016) Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J 57(1):77–79
Lucijanic M, Skelin M, Lucijanic T (2017) Survival analysis, more than meets the eye. Biochem Med 27(1):14–18
Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH (2012) Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 141(1):147–153
Vassilikos V, Dakos G, Chouvarda I, Karagounis L, Karvounis H, Maglaveras N, Mochlas S, Spanos P, Louridas G (2003) Can P wave wavelet analysis predict atrial fibrillation after coronary artery bypass grafting? Pacing Clin Electrophysiol 26:305–309
Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY (2016) Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 203:660–666
Sobue Y, Watanabe E, Lip GYH, Koshikawa M, Ichikawa T, Kawai M, Harada M, Inamasu J, Ozaki Y (2018) Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart Vessels 33(4):403–412
Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, Investigators C (2017) Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19(10):1258–1269
Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 15(4):776–785
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Rights and permissions
About this article
Cite this article
Jurin, I., Lucijanic, M., Jurin, H. et al. Patients with atrial fibrillation and mid-range ejection fraction differ in anticoagulation pattern, thrombotic and mortality risk independently of CHA2DS2-VASC score. Heart Vessels 35, 1243–1249 (2020). https://doi.org/10.1007/s00380-020-01603-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-020-01603-2